Statins and Ezetimibe

PreclinicalSmall molecule

Statins and Ezetimibe is one of 6 small molecule programs targeting Familial Hypercholesterolemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial HypercholesterolemiaActive, not recruiting

Familial HypercholesterolemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Familial Hypercholesterolemia

#DrugCompanyPhaseTrials

Niacor

Leqvio

4 3

QLC7401

Qilu Pharmaceutical Co., Ltd.

Phase 3

2 4

Atorvastatin Calcium

YOLT-101

2 6

Statins and Ezetimibe

UUniversity of Sao Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial Hypercholesterolemia1 trial

Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe

Unknown status·UUniversity of Sao Paulo·N/A·NCT00475826

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Statins and Ezetimibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Statins and Ezetimibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Statins and Ezetimibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Sao Paulo

Statins and Ezetimibe

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial Hypercholesterolemia1 trial

References

Drug Info

Quick Facts

Related News